✅ Model Answer:
• Multiple fractures – healing and healed fractures at various stages.
• Bowed long bones – femoral and tibial bowing (especially in Type III).
• Osteopenia – decreased bone density with thin cortices.
• Popcorn calcifications – metaphyseal areas (Type III).
• Diagnosis: Osteogenesis imperfecta (likely Type III or IV).

✅ Model Answer:
• Multiple fractures – at various stages of healing (acute, healing, healed).
• Bowed long bones – especially femur and tibia (Type III).
• Osteopenia – decreased bone density, thin cortices, and trabecular rarefaction.
• Popcorn calcifications – nodular calcifications in the metaphyses (Type III).
• Thin cortices – with medullary expansion (due to multiple fractures).
• Wormian bones – on skull X-ray (intrasutural bones).
• "Bone-within-bone" appearance – may be seen in some cases.

✅ Model Answer:
• Osteogenesis imperfecta (OI) is a genetic disorder caused by mutations in the COL1A1 and COL1A2 genes (type I collagen).
• Type I collagen is the most abundant protein in bone, skin, tendons, ligaments, and dentin.
• Mutations:
- COL1A1 (chromosome 17) – more common in Type I.
- COL1A2 (chromosome 7) – less common.
• The mutations lead to reduced production or structural defects in type I collagen → bone fragility and reduced bone density.
• This results in brittle bones that fracture easily with minimal trauma.
• Inheritance: Autosomal dominant (most cases), autosomal recessive (rare).
• Other features: Blue sclerae (thinned sclera), dentinogenesis imperfecta, hearing loss.

✅ Model Answer:

Type	Sclerae	Severity	Key Features
Type I	Blue	Mild	Fractures in childhood, hearing loss (20-30%), normal stature, dentinogenesis imperfecta (mild)
Type II	Blue	Lethal	Perinatal death, multiple fractures in utero, crumpled femurs, beaded ribs
Type III	White	Severe	Bowed femurs, progressive deformity, short stature, triangular facies, popcorn calcifications
Type IV	White	Moderate	Variable fractures, short stature, dentinogenesis imperfecta (common)

✅ Model Answer:
• Medical management:
1. Bisphosphonates: IV pamidronate (or zoledronic acid) – increases bone density and reduces fracture risk. Protocol: 1 mg/kg/day IV for 3 consecutive days, repeated every 3-4 months.
2. Calcium and vitamin D supplementation: To support bone health.
3. Pain management: Analgesics for acute fractures.
• Surgical management:
1. Intramedullary rodding: Telescoping rods (Sofield-Millar) to straighten and stabilize bowed long bones.
2. Fracture fixation: For acute fractures.
• Rehabilitation:
1. Physical therapy: To maintain muscle strength and joint mobility.
2. Occupational therapy: For daily living activities.
3. Hydrotherapy: To improve mobility with low impact.
• Multidisciplinary care: Genetics, orthopedics, dentistry, audiology, and physiotherapy.

✅ Model Answer:
• Bisphosphonates (pamidronate, zoledronic acid) are the mainstay of medical therapy for OI.
• Mechanism: Inhibit osteoclast-mediated bone resorption → increase bone mineral density (BMD) and reduce fracture risk.
• Indications:
- Moderate to severe OI (Types III, IV).
- Recurrent fractures.
- Bone pain.
- Vertebral compression fractures.
• Benefits: Reduces fracture rate by 30-50%, improves mobility, decreases bone pain, and improves growth.
• Monitoring: Calcium, vitamin D levels, renal function, and dental health (bisphosphonates can cause jaw osteonecrosis).
• Side effects: Flu-like symptoms (fever, myalgia) – usually with the first infusion.

✅ Model Answer:
• Hearing loss in OI is common in Type I (up to 30-40% by adulthood).
• Types:
- Conductive: Due to otosclerosis-like changes in the middle ear (stapes fixation).
- Sensorineural: Due to cochlear damage from otic capsule involvement.
• Management:
1. Audiology referral: Regular hearing assessments.
2. Hearing aids: For conductive or mixed hearing loss.
3. Cochlear implants: For severe sensorineural hearing loss.
4. Stapedectomy: May be considered for conductive hearing loss (risk of complications).
5. Monitoring: Annual hearing tests.

✅ Model Answer:
• Dentinogenesis imperfecta (DI) is a dental manifestation of OI, characterized by translucent, discolored teeth (gray/yellow/brown).
• Features: Thin enamel, prone to wear, discoloration, and early tooth loss.
• Management:
1. Pediatric dentist referral: Early evaluation is essential.
2. Restorative dental care: Crowns, fillings, and bonding to protect teeth.
3. Fluoride treatment: To prevent caries.
4. Monitor: For dental abscesses and early tooth loss.
5. Prosthetics: May be needed for severe tooth loss.
6. Avoid: Aggressive dental extractions (risk of fracture).

✅ Model Answer:
• Type III OI has a severe prognosis – progressive deformity, short stature, and disability.
• With modern care (bisphosphonates, rodding, physical therapy), many patients survive into adulthood.
• Complications:
- Respiratory insufficiency – due to chest wall deformity.
- Basilar invagination – can cause neurological symptoms.
- Chronic pain and disability.
- Hearing loss (may develop).
- Early-onset osteoarthritis.
• Quality of life: Improved with multidisciplinary care, but many patients require lifelong support.
• Mortality: Higher than the general population, but improved with aggressive management.

✅ Model Answer:

Feature	Osteogenesis Imperfecta	Child Abuse
Blue sclerae	Present (Type I)	Absent
Dentinogenesis imperfecta	Present	Absent
Fracture pattern	Multiple fractures at various stages (healing/healed), bowed bones	Fractures at different healing stages, often in different locations
Bone density	Osteopenia	Normal
Family history	Often positive	Negative